15 completed. 15 Phase 2, 5 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Completed 15 |
| Phase 1 | 5 | Completed 5 |
| Phase 3 | 1 | Completed 1 |
Follow Granuloma: new trials by email Literature Review of Granuloma trials Research Report on Granuloma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Janus Kinase Inhibition in Granuloma Annulare Abrocitinib 200 mg - Granuloma Annulare | Phase 2 | Completed | William Damsky | 10 | 2023-10-27 | 2026-10-07 |
| The Efficacy of Laser in Root Canal Disinfection Conventional group (NaOCl/EDTA), Dual laser group (Er,Cr:YSGG/Diode):, Combined group (EDTA/Diode): - Pulp and Periapical Tissue Disease, Pulp Necroses | Phase 2 | Completed | Future University in Egypt | 30 | 2022-01-01 | 2023-11-29 |
| Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis Naltrexone Hydrochloride, Placebo Comparator - Eosinophilic Granulomatosis With Polyangiitis (EGPA), Churg-Strauss Syndrome (CSS) | Phase 2 | Completed | University of Pennsylvania | 60 | 2019-02-04 | 2026-01-22 |
| Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis Efzofitimod 1.0 mg/kg or Placebo, Efzofitimod 3.0 mg/kg or Placebo, Efzofitimod 5.0 mg/kg or Placebo - Pulmonary Sarcoidosis | Phase 1 / Phase 2 | Completed | aTyr Pharma, Inc. | 37 | 2019-01-29 | 2023-07-18 |
| Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Patients With Pulmonary Sarcoidosis ACZ885, Placebo - Pulmonary Sarcoidosis | Phase 2 | Completed | Novartis Pharmaceuticals | 40 | 2016-12-19 | 2021-10-04 |
| Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Doxorubicin, Doxorubicin Hydrochloride, Ifosfamide - Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma | Phase 2 / Phase 3 | Completed | National Cancer Institute (NCI) | 140 | 2014-08-12 | 2026-06-17 |
| CREATE: Cross-tumoral Phase 2 With Crizotinib Crizotinib (PF-02341066) - Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma, Locally Advanced and/or Metastatic Inflammatory Myofibroblastic Tumor | Phase 2 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 582 | 2012-09-01 | 2023-12-11 |
| Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells Hematopoietic stem cell transplantation - Sickle Cell Disease, Thalassemia | Phase 1 / Phase 2 | Completed | Children's Hospital Los Angeles | 25 | 2008-08-01 | 2016-06-23 |
| Safety and Efficacy Study of Mepolizumab in Churg Strauss Syndrome mepolizumab - Churg Strauss Syndrome | Phase 2 | Completed | University Hospital Schleswig-Holstein | 10 | 2008-07-01 | 2012-06-15 |
| Mepolizumab As a Steroid-sparing Treatment Option in the Churg Strauss Syndrome Mepolizumab - Churg Strauss Syndrome | Phase 1 / Phase 2 | Completed | Brigham and Women's Hospital | 10 | 2007-09-01 | 2017-03-22 |
| Efficacy of Nasal Spray Calcitonin on Recurrence of Aggressive Central Giant Cell Granuloma nasal spray calcitonin, Placebo - Central Giant Cell Granuloma | Phase 2 | Completed | Shiraz University of Medical Sciences | 24 | 2007-09-01 | 2015-05-21 |
| 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis tanespimycin - Chronic Myeloproliferative Disorders, Leukemia | Phase 2 | Completed | National Institutes of Health Clinical Center (CC) | 37 | 2006-05-01 | 2012-03-15 |
| Ultraviolet B (UVB) Light Therapy in the Treatment of Skin Conditions With Altered Dermal Matrix UVB Irradiation - Keloid, Scleroderma, Localized | Phase 1 / Phase 2 | Completed | University of Michigan | 33 | 2002-08-01 | 2015-05-01 |
| Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome Mepolizumab - Hypereosinophilic Syndromes, Eosinophilic Gastroenteritis | Phase 1 / Phase 2 | Completed | Children's Hospital Medical Center, Cincinnati | 24 | 2001-12-01 | 2020-07-29 |
| Treatment of Wegener's Granulomatosis With Cyclophosphamide cyclophosphamide - Vasculitis, Wegener's Granulomatosis | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 200 | 1976-02-01 | 2008-03-04 |
Churg-Strauss Syndrome (4) · Granuloma Annulare (2) · Granuloma, Plasma Cell (2) · Granulomatosis with Polyangiitis (2) · Inflammation (2) · Lymphoproliferative Disorders (2) · Sarcoidosis (2) · Sarcoidosis, Pulmonary (2) · Sarcoma, Alveolar Soft Part (2) · Sarcoma, Clear Cell (2) · Acne Keloid (1) · Anemia (1) · Anemia, Dyserythropoietic, Congenital (1) · Anemia, Sickle Cell (1)
Hemic and Lymphatic Diseases (11) · Lymphatic Diseases (11) · Pathologic Processes (11) · Pathological Conditions, Signs and Symptoms (11) · Immune System Diseases (10) · Lymphoproliferative Disorders (9) · Skin and Connective Tissue Diseases (9) · Skin Diseases (8) · Cardiovascular Diseases (6) · Vascular Diseases (6) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (5) · Autoimmune Diseases (5) · Skin Diseases, Vascular (5) · Systemic Vasculitis (5)
mepolizumab (3) · Crizotinib (1) · Cyclophosphamide (1) · Doxorubicin (1) · Hematopoietic Stem Cell Transplantation (1) · Ifosfamide (1) · Naltrexone (1) · Radiation (1) · Radiotherapy (1) · abrocitinib (1) · canakinumab (1) · pazopanib (1) · tanespimycin (1)
Brigham and Women's Hospital (1) · Children's Hospital Los Angeles (1) · Children's Hospital Medical Center, Cincinnati (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Future University in Egypt (1) · National Cancer Institute (NCI) (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · National Institutes of Health Clinical Center (CC) (1) · Novartis Pharmaceuticals (1) · Shiraz University of Medical Sciences (1) · University Hospital Schleswig-Holstein (1) · University of Michigan (1) · University of Pennsylvania (1) · William Damsky (1) · aTyr Pharma, Inc. (1)
United States (11) · Germany (3) · Canada (2) · Netherlands (2) · Belgium (1) · Egypt (1) · France (1) · Iran (1) · Italy (1) · Norway (1) · Poland (1) · Puerto Rico (1) · Slovakia (1) · Slovenia (1) · United Kingdom (1)
Aaron R Weiss (1) · Antonio T. Fojo, MD, PhD (1) · Gennyne Walker (1) · Hisham Abdel-Azim, MD (1) · John J Voorhees, MD (1) · Marc E. Rothenberg, MD (1) · Michael Wechsler, MD (1) · Peter A Merkel, MD, MPH (1) · Sorena Fardisi, DMD (1) · William Damsky, M.D. (1)
PMID 28950372, PMID 29216400, PMID 29567632, PMID 29669701, PMID 32702309, PMID 32827353, PMID 34392187, PMID 34515544, PMID 36356657, PMID 37523624, PMID 37854715
U10CA098543 (1), U10CA180830 (1), U10CA180886 (1)